Compare Incyte Corporation (INCY) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Kaltura Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Kaltura Inc trades at $1.32 (market cap $199.08M). The key difference: Incyte Corporation is far larger — about 114.8× Kaltura Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Kaltura Inc for 21 Days on average.
| INCY | KLTR | |
|---|---|---|
Market Cap | $22.85B | $199.08M |
Volume | 1,927,029 | 175,927 |
Sector | Health | Technology |
52-Week High | $129.93 | $1.89 |
52-Week Low | $83.80 | $1.08 |
Typical Hold Time | 33 Days | 21 Days |
Enterprise Value | $18.35B | $211.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
KLTR trades at $1.305, down 1.88% for the day, with a bearish technical signal from moving averages. The company reported revenue of $180.85M for 2025 but remains unprofitable with a net loss of $12.07M, though losses have narrowed significantly since 2022. Recent news highlights include winning the 2026 Digiday Technology Award and being named a leader by Gartner in AI for video platform services.
The outlook is mixed: analyst consensus leans buy (44% buy ratings), and the company shows improving financial trends, but high valuation ratios and persistent net losses present risks. Key catalysts include the commercial rollout of AI products, while execution risks and competitive pressures remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
